Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

Highlights • HER2 overexpression is associated with poor prognosis in breast cancer. • Trastuzumab (anti-HER2) is effective in treating HER2-positive breast cancer. • pT1a,b N0M0 breast cancers have an excellent prognosis across all subgroups. • Prognostic factors in pT1a,b N0M0 HER2-positive breast...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-02, Vol.43, p.1-7
Hauptverfasser:	Musolino, Antonino, Boggiani, Daniela, Sikokis, Angelica, Rimanti, Anita, Pellegrino, Benedetta, Vattiato, Rosa, Sgargi, Paolo, Falcini, Fabio, Caminiti, Caterina, Michiara, Maria, Leonardi, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Chemotherapy, Adjuvant - methods Clinical Decision-Making Disease-Free Survival Female Hematology, Oncology and Palliative Medicine HER2-positive Humans Interval cancer risk Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - prevention & control Neoplasm Staging Prognosis Prognostic factors pT1a,b Receptor, ErbB-2 - metabolism Risk Assessment - methods Risk Factors Trastuzumab - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • HER2 overexpression is associated with poor prognosis in breast cancer. • Trastuzumab (anti-HER2) is effective in treating HER2-positive breast cancer. • pT1a,b N0M0 breast cancers have an excellent prognosis across all subgroups. • Prognostic factors in pT1a,b N0M0 HER2-positive breast cancers are lacking. • The prognostic role of interval cancer detection is suggested.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2015.11.010